Licensing Marketing Patent Application Settlement 
Bio Law Blog
JUNE 21, 2020
settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc.
The IPKat
AUGUST 16, 2021
Over to Konstantin for the story and his take on the developments: "Some may associate businesses whose primary aim is to assert patents in litigation to obtain license revenue with the Eastern District of Texas or the Unwired Planet decision in the UK, and not think about cases further afield from Marshall, Texas or London.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
IP Tech Blog
NOVEMBER 15, 2023
Cloudbreak Therapeutics, LLC , provides some interesting insights into patent challenge strategies, and their consequences, when a potentially infringing product is not yet on the market. An Allgenesis executive testified by declaration that the parties were unable to reach a settlement.
LexBlog IP
NOVEMBER 15, 2023
Cloudbreak Therapeutics, LLC , provides some interesting insights into patent challenge strategies, and their consequences, when a potentially infringing product is not yet on the market. An Allgenesis executive testified by declaration that the parties were unable to reach a settlement.
IP and Legal Filings
JANUARY 21, 2022
With vigorous marketing of patent portfolios, it becomes necessary that those dispute settlements must be done on an amicable basis. Also, Huawei wants to have a strong patent portfolio in the Chinese market where all such measures are more or less beneficial for it. Chinese market.
LexBlog IP
DECEMBER 30, 2021
As we previously reported , the Consolidated Appropriations Act, enacted in December 2020, contained a provision that required FDA to create a searchable, electronic database of biologics and to update it with patent information provided by the Reference Product Sponsor to an applicant during the patent dance.
Intepat
JUNE 19, 2023
It may be because the owner has enough capabilities for carrying out the marketing themselves, or does not have enough resources for entering into a partnership for the same or simply because the owner is hesitant to share their data with third parties. It also reduces the distribution and marketing expenses to an extent.
Expert insights. Personalized for you.
52 
Let's personalize your content